KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Gross Margin (2016 - 2025)

Historic Gross Margin for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q3 2025 value amounting to 86.52%.

  • Vertex Pharmaceuticals' Gross Margin rose 6800.0% to 86.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 86.28%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 86.11% for FY2024, which is 11000.0% down from last year.
  • Vertex Pharmaceuticals' Gross Margin amounted to 86.52% in Q3 2025, which was up 6800.0% from 86.25% recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Margin peaked at 88.85% during Q1 2021, and registered a low of 85.38% during Q4 2023.
  • Its 5-year average for Gross Margin is 87.21%, with a median of 87.29% in 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Gross Margin surged by 7900bps in 2022 and then tumbled by -23100bps in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Margin (Quarter) stood at 88.06% in 2021, then decreased by 0bps to 87.7% in 2022, then decreased by -3bps to 85.38% in 2023, then increased by 0bps to 85.46% in 2024, then increased by 1bps to 86.52% in 2025.
  • Its last three reported values are 86.52% in Q3 2025, 86.25% for Q2 2025, and 86.9% during Q1 2025.